Abstract
The mechanism by which physostigmine exerts its behavioral, neuroendocrine and cardiovascular effects was explored in two separate experiments. In the first, the centrally-acting cholinesterase inhibitor physostigmine was compared with the non-centrally-acting agent neostigmine. In contrast to physostigmine, neostigmine caused no effects. In the second experiment, pretreatment with scopolamine, in contrast to methscopolamine, attenuated physostigmine's effects. The results suggest that physostigmine exerts its effects via a central muscarinic mechanism.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
